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ABSTRACT 
BACKGROUND:  Accurate differentiation of pancreatic cystic lesions is important for 
pancreatic cancer early detection and prevention as well as avoidance of unnecessary surgical 
intervention.  Serous cystic neoplasms (SCN) have no malignant potential, but may mimic 
premalignant mucinous cystic lesions:  mucinous cystic neoplasm (MCN) and intraductal 
papillary mucinous neoplasm (IPMN). We recently identified vascular endothelial growth factor 
(VEGF)-A as a novel pancreatic fluid biomarker for SCN. We hypothesize that combining cyst 
fluid carcinoembryonic antigen (CEA) with VEGF-A will improve the diagnostic accuracy of 
VEGF-A.    
METHODS: Pancreatic cyst/duct fluid was collected from consenting patients undergoing 
surgical cyst resection with corresponding pathologic diagnoses. Pancreatic fluid VEGF-A and 
CEA levels were detected by ELISA.  
RESULTS: One hundred forty-nine patients with pancreatic cystic lesions met inclusion criteria. 
Pathologic diagnoses included pseudocyst (n=14), SCN (n=26), MCN (n=40), low/moderate 
grade IPMN (n=34), high grade IPMN (n=20), invasive IPMN (n=10) and solid pseudopapillary 
neoplasm (n=5). VEGF-A was significantly elevated in SCN cyst fluid compared to all other 
diagnoses (p<0.001). With a threshold of >5,000 pg/ml, VEGF-A alone has 100% sensitivity and 
83.7% specificity to distinguish SCN from other cystic lesions. With a threshold of ≤10ng/ml, 
CEA alone identifies SCN with 95.5% sensitivity and 81.5% specificity. Sensitivity and 
specificity of the VEGF-A/CEA combination are 95.5% and 100% respectively. The c-statistic 
increased from 0.98 to 0.99 when CEA was added to VEGF-A alone in the ROC analysis. 
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CONCLUSIONS: Although VEGF-A alone is a highly accurate test for SCN, the combination 
of VEGF-A with CEA approaches the gold-standard of pathologic diagnosis, thus importantly 
avoiding false positives. Patients with a positive test indicating benign SCN can be spared a high 
risk surgical pancreatic resection. 
Key Words: pancreatic cyst fluid, pancreatic cancer prevention, VEGF, CEA, biomarker 
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Abbreviations 
IPMN: Intraductal papillary mucinous neoplasm 
MCN: Mucinous cystic neoplasm 
SCN: Serous cystic neoplasm 
VEGF-A: Vascular endothelial growth factor A 
CEA: Carcinoembryonic antigen 
SPN: Solid pseudopapillary neoplasm 
ROC: Receiver operator curve 
VHL: Von Hippel Lindau 
PNET: Pancreatic neuroendocrine tumor 
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Introduction 
 Pancreatic cysts are increasingly diagnosed due to advancements in radiographic imaging 
allowing for higher diagnostic sensitivity and higher test volume. 2.6% of patients undergoing 
abdominal imaging will have incidentally diagnosed cystic lesions of the pancreas.1 Pancreatic 
cysts can be differentiated based upon malignant potential. While mucinous cysts such as 
intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN) harbor 
malignant potential, serous cystic neoplasm (SCN) and pseudocysts virtually never progress to 
invasive carcinoma.2 Consequently, management ranges from observation to aggressive 
pancreatic resection. Pancreatic surgery is associated with significant mortality and morbidity in 
the contemporary literature.3 Diagnostic accuracy is therefore of paramount importance.  
 SCN is a benign lesion that represents 16% of resected pancreatic cysts and less than 1% 
of all pancreatic lesions.4, 5 Only three serous cystadenocarcinomas were found within the largest 
series of SCN patients to date (n = 2,622), demonstrating the extremely low rate of malignant 
progression.6 Furthermore, SCN-specific mortality approaches nil at 0.1%.6 For these reasons, in 
addition to the low rate of symptoms, the majority of SCN can be managed non-operatively.6-8 
Despite this, the retrospective multinational series by Jais et al. found only 39% of SCN patients 
avoid surgical resection.6 Major indications for surgery included presence of symptoms, cyst size 
or growth rate, and lack of pre-operative diagnosis (60%).6 While exact thresholds for cyst size 
or growth rate are controversial, most agree that diagnostic uncertainty is unacceptable.2, 7, 9, 10 
Existing diagnostic modalities (CT, MRI, endoscopic ultrasound, and fine-needle 
aspiration with cyst fluid analysis) are imperfect and leave many cysts undiagnosed or 
incorrectly diagnosed.8, 11 Biomarker research is being pursued in hopes of improving the 
diagnostic accuracy of pancreatic cysts. However, the majority of emerging biomarker 
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investigations focus on mucinous cysts with malignant potential. It is equally important to 
develop diagnostic tools for benign lesions in order to avoid unnecessary morbidity and mortality 
of surgery. We previously identified vascular endothelial growth factor (VEGF)-A as a valuable 
pancreatic fluid biomarker for differentiating benign SCN from all other pancreatic cysts.12 In the 
present study, we aim to further validate VEGF-A in a larger cohort and establish an improved 
VEGF-A/CEA diagnostic test for SCN. This test will facilitate avoidance of unnecessary 
pancreatic resection for SCN. 
  
Methods 
Patient Samples 
Samples were either obtained from the Indiana University Pancreatic Tissue-Fluid Bank 
following approval by Indiana University Institutional Review Board or kindly provided by 
Johns Hopkins University (n=12, Dr. Anne Marie Lennon). Patients signed informed consent for 
collection of pancreatic fluid at the time of routine endoscopy (EUS or ERCP) and/or operation 
(OR).  We have previously confirmed that the method of fluid procurement does not affect 
VEGF-A measurement.12 Fluid specimens were placed immediately on ice after procurement and 
aliquoted for storage at -80 degrees.  In total, samples from 149 patients collected between 2003 
and 2015, including serous cystic neoplasm (SCN, n=26), pseudocyst (n=14), mucinous cystic 
neoplasm (MCN, n=40), intraductal papillary mucinous neoplasm (IPMN) low/moderate grade 
(n=34) or high-grade (n=20) or invasive (n=10), and solid pseudopapillary neoplasm (SPN, n=5), 
were pathologically confirmed following surgical resection.  IPMN dysplasia was determined 
according to the World Health Organization (WHO) criteria. VEGF-A levels were previously 
reported for 87 of these patients. 
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VEGF-A and CEA measurement 
Pancreatic fluid samples (1-50ul) were analyzed for VEGF-A by Quantikine ELISA (R&D 
Systems, Minneapolis, MN) according to the manufacturer’s protocol.  CEA was determined by 
Beckman Coulter DxI 800 analyzer or in cases of low fluid volume, by ELISA (Sigma-Aldrich, 
St. Louis, MO).  CEA values obtained by ELISA were converted to the Beckman automated 
analyzer scale using linear regression.  
 
Molecular Genetic Analysis of Von Hippel Lindau (VHL) 
DNA was extracted from 3 SCN samples and their matched adjacent normal tissue using the 
QIAamp DNA Mini Kit (Qiagen, Valencia, CA).  A custom multiplex PCR reaction capturing all 
coding exons and significant portions of introns and UTRs was designed using the Ion Torrent 
Ampliseq Designer (Life Technologies, South San Francisco, CA).  Barcoded libraries were 
prepared using the Ion Ampliseq Kit for Chef DL8 (A29024, ThermoFisher Scientific), followed 
by sequencing using Ion Hi-Q Sequencing Technology.  Sequencing data was mapped to the 
human genome (hg19) and analyzed for somatic mutations using the Ion Torrent Suite v5.0.3 and 
Ion Reporter v5.2.                 
 
Statistical Analysis 
Descriptive statistics including mean, median, and range were calculated for each cyst type. 
VEGF-A and CEA were analyzed for statistical significance using Kruskal-Wallis for all groups 
and Wilcoxon Rank Sum test for SCN versus non-SCN comparisons as our data was not 
normally distributed. P-values of <0.05 were considered statistically significant. Receiver 
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operator characteristic (ROC) curve analysis was further used to evaluate the diagnostic accuracy 
of each biomarker test. Cut-points for VEGF-A and CEA were then chosen using Youden’s 
index for the combined VEGF-A and CEA tests. In this case, the test was classified as positive 
for SCN if the thresholds for both VEGF-A and CEA were met, and negative if either of the 
thresholds were not met. We then modified the thresholds after examining the data to minimize 
false positives for SCN. These thresholds were then used to calculate the sensitivity, specificity, 
and likelihood ratios of VEGF-A and CEA alone and in combination.  
 
Results 
VEGF-A levels in pancreatic fluid 
 Patient pancreatic fluid samples (n=149) were collected from cystic lesions of the 
pancreas and correlated with surgical pathologic diagnosis.  These included 26 serous cystic 
neoplasms (SCN), 14 pseudocysts, 40 mucinous cystic neoplasms (MCN), 5 solid 
pseudopapillary neoplasms (SPN), and 64 intraductal papillary mucinous neoplasms (IPMN). 
IPMN was further divided based on grade of dysplasia according to WHO criteria: 34 (22.8%) 
low to moderate grade dysplasia, 20 (13.4%) high grade dysplasia, and 10 (6.7%) invasive 
IPMN.  
Pancreatic fluid samples were analyzed for VEGF-A by ELISA (Figure 1).  Median 
VEGF-A concentrations and ranges were as follows for SCN: 35,598 (5,318 – 290,960 pg/mL), 
pseudocyst: 1283 (0 – 16,204 pg/mL), MCN: 2,074 (6 – 15,233 pg/mL), low/moderate grade 
IPMN: 2,285 (753 – 9,483 pg/mL), high grade IPMN: 2,951 (30 – 16,324 pg/mL), invasive 
IPMN: 4,341 (1,184 – 19,555 pg/mL), and SPN: 295 (151 – 584 pg/mL). VEGF-A level in SCN 
cyst fluid was significantly higher than VEGF-A in non-SCN pancreatic fluid (35,598 vs 2,149 
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pg/mL; p<0.0001), and likewise higher compared to each specific cyst group (p<0.0001), 
confirming our previously published findings. Additionally, Von Hippel-Lindau (VHL) status 
was determined in three SCN patients with elevated cyst fluid VEGF levels, for which cyst tissue 
and matching normal adjacent tissue were available.  Genetic alterations that inactivate the tumor 
suppressor VHL may result in upregulated VEGF expression.  Indeed, VHL gene alterations 
were detected in the three SCNs – one with a point mutation/splice site alteration 
(chr3:10188197G>A) and two with deletions/frameshifts (chr3:10183820 and 10183845), 
confirming our previous report. 
 VEGF-A concentration of greater than 5,000 pg/mL was chosen as the threshold for a 
positive diagnostic test to detect SCN. This threshold was chosen to maximize sensitivity and 
specificity of the VEGF-A/CEA combination test. Using this criterion for VEGF-A, all SCNs 
were correctly classified with a sensitivity of 100%. Twenty non-SCN pancreatic cysts (1 
pseudocyst, 7 MCN, 5 low/moderate grade IPMN, 4 high grade IPMN, and 3 invasive IPMN) 
were incorrectly categorized as SCN by this VEGF-A threshold, demonstrating a specificity of 
83.7%. The highest non-SCN VEGF-A was an invasive IPMN at 19,555 pg/mL. The positive 
and negative likelihood ratios were 6.2 and 0; a negative VEGF-A test was 100% accurate. ROC 
curve analysis revealed AUC of 0.983 (Figure 2).  With an alternate VEGF-A threshold of 7,858 
pg/mL chosen to maximize sensitivity/specificity of the single test, sensitivity and specificity 
were 96.2% and 91.9%. Thus, VEGF-A alone is an accurate SCN biomarker; however, a clinical 
diagnostic test for benign SCN must achieve 100% specificity to avoid misclassification of 
potentially malignant pancreatic cysts, or false positives. 
 
CEA levels in pancreatic fluid 
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Of the 149 pancreatic fluids tested for VEGF-A, 130 had sufficient volume available for 
determination of CEA concentration (Figure 3). Median CEA levels and ranges were as follows 
for SCN: 0.5 (0.09 – 65.4 ng/mL), pseudocyst: 20.4 (0.5 – 310 ng/mL), MCN: 1,000 (0.1 – 
25,194 ng/mL), low/moderate grade IPMN: 244 (0.8 – 511,473 ng/mL), high grade IPMN: 260.5 
(2.9 – 7,550 ng/mL), invasive IPMN: 1,878 (3.2 – 38,730 ng/mL), and SPN: 0.1 (0.1 – 0.1 
ng/mL). CEA level in SCN cyst fluid was significantly lower than CEA in non-SCN pancreatic 
fluid (p<0.0001), and likewise lower compared to each specific cyst group (p<0.0001). A 
pancreatic fluid CEA threshold of less than 10 ng/ml was considered a positive diagnostic test 
for SCN. Using this criterion, one SCN was misclassified with a CEA of 65.4 ng/mL and twenty 
non-SCN cysts were incorrectly categorized as SCNs.  This demonstrates that pancreatic fluid 
CEA has a sensitivity and specificity of 95.5% and 81.5%, respectively, to detect SCN. Positive 
and negative likelihood ratios were 5.2 and 0.06. ROC curve analysis resulted in AUC of 0.945 
for CEA alone (Figure 2). 
 
VEGF-A/CEA combination test for SCN 
 We sought to determine whether combining VEGF-A with CEA could improve the 
diagnostic accuracy of VEGF-A as a biomarker of SCN.  Both VEGF-A greater than 5,000 
pg/mL and CEA less than 10 ng/mL was considered a positive combination test for SCN (Figure 
4). Of the cysts analyzed for CEA (SCN: n=22; non-SCN: n=108), none of the other pancreatic 
cysts (non-SCN) cysts had a positive combination test, and only one SCN was misclassified with 
a negative test. Sensitivity and specificity of VEGF-A/CEA were 95.5% and 100%, respectively, 
with an infinite positive likelihood ratio. The single SCN outlier had VEGF-A of 104,275 pg/mL 
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and CEA of 65.4 ng/mL. AUC for the VEGF-A/CEA combination was 0.993 on ROC analysis, 
an improvement over each biomarker alone (Figure 2).  
 
Diagnostic utility of VEGF-A/CEA test 
 To evaluate the potential diagnostic utility of the VEGF-A/CEA test for SCN, we 
reviewed the indications for surgery of the SCN cohort (Figure 5). Surgical indications included 
unclear diagnosis, presence of symptoms, cyst size, cyst growth, young patient age, and patient 
preference. All patients underwent at least two diagnostic modalities (CT and EUS-guided FNA), 
with twelve patients (50%) undergoing three or greater (including MRI/MRCP, ERCP, or PET). 
Despite the abundance of diagnostic methodologies, preoperative diagnoses in patients with SCN 
were often unclear or unknown (n=15, 63%). Patients with multiple diagnoses, most commonly 
MCN or IPMN, were also categorized as “unclear diagnoses.” Unclear diagnosis was the most 
common indication for surgical resection. 25% (n=6) of patients underwent operative 
management for the sole indication of unclear or unknown diagnosis. Importantly, all of these 
patients would have been identified as SCN with a positive VEGF-A/CEA diagnostic test and 
therefore avoided major surgery. 
 
Discussion 
Optimal clinical management of pancreatic cysts with variable malignant potential relies 
upon accurate differential diagnosis to stratify patient risk. Currently, SCN diagnosis is most 
commonly made by radiographic appearance, a highly variable, imprecise modality for 
pancreatic cysts with overlapping features.7 SCN are described as microcystic, macrocystic, 
mixed, or solid type by Kimura et al.8 Microcystic SCN are composed of multiple, small (<1 cm) 
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cysts lined by glycogen rich cuboidal epithelium, similar in appearance to a honeycomb.5, 7, 13 
The classically described central scar is present in only 15-20%. Microcystic SCN account for 
the majority of SCN and are the most diagnostically straightforward. Alternatively, macrocystic 
SCN are composed of one or several larger cysts (>1 cm), a pattern shared by some IPMN and 
MCN.7, 8 Multiple studies have found low sensitivity and specificity of radiographic imaging for 
SCN diagnosis, supporting this diagnostic challenge. In a study by Bassi et al., SCN was 
correctly diagnosed by CT and MRI 54% and 74% of the time, and incorrectly diagnosed 34% 
and 26% of the time.11 Kimura et al. later reported 63% of resected SCN were not pre-
operatively diagnosed as such.8 Alternative diagnoses included IPMN (most commonly), cystic 
pancreatic neuroendocrine tumors (PNET), and MCN. In support, we report here that 63% of 
SCN were preoperatively misdiagnosed/not diagnosed.  
 Endoscopic ultrasound (EUS) with or without fine-needle aspiration (FNA) is the next 
step in pancreatic cyst diagnosis, but still often fails to accurately diagnose the cyst.11 EUS alone 
has a sensitivity and specificity similar to CT with many of the same diagnostic difficulties and 
the added drawback of being an invasive procedure.11 Although all SCN patients included in this 
series underwent at least CT and EUS imaging, a high rate of uncertain diagnoses were still 
observed. No patients with SCN had 100% certain diagnoses preoperatively, as none underwent 
the gold-standard core biopsy with pathologic evaluation. Core biopsy is not recommended for 
the routine diagnosis and management of pancreatic cysts. FNA may be added for additional 
diagnostic options but also has significant shortcomings. Cytologic analysis is often not possible 
due to pauci- or acellular aspirate accounting for the low sensitivity of FNA.14-16 Molecular 
genetics may offer further diagnostic clues. Although not universal, K-RAS and GNAS 
mutations are common in mucinous pancreatic cysts, unlike non-mucinous SCN.17, 18 Von Hippel 
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Lindau (VHL) tumor suppressor gene mutations are also associated with SCN development and 
may be present in hereditary forms of SCN.19, 20 However, sporadic SCN are vastly more 
prevalent, and VHL mutations may be associated with SCN as well as PNET.  
Cyst fluid carcinoembryonic antigen (CEA) has repeatedly proven useful in 
differentiating mucinous from non-mucinous pancreatic cysts. CEA level cutoffs vary widely, 
resulting in equally diverse reports of diagnostic accuracy. 192 ng/mL is a commonly accepted 
CEA threshold that was found to yield a diagnostic accuracy of 79%, better than all other tests 
evaluated (EUS, cytology, CA 125, and CA 19-9).21 Similar studies report accuracy ranging 
from 70-86%, sensitivity of  61-89%, and specificity of 63-77%, using CEA thresholds of 5-800 
ng/mL.22-26 CEA has also been used as part of combination tests to achieve further diagnostic 
accuracy; however, none of these specifically identify SCN.25, 27, 28  
A diagnostic test for SCN must be near perfect to avoid the consequences of misdiagnosis 
(i.e. unnecessary surgery of benign lesions or surveillance of potentially malignant lesions).  We 
previously identified VEGF-A as a highly accurate pancreatic fluid biomarker for SCN.12 These 
findings were validated in the present study with a larger cohort from two institutions. 
Additionally, we demonstrated that combining cyst fluid CEA with VEGF-A achieves 95.5% 
sensitivity and 100% specificity as a diagnostic test for SCN. To our knowledge, the VEGF-
A/CEA combination is the only SCN-specific, highly accurate test reported in the literature to 
date. Although two small studies report alpha-inhibin as a highly sensitive immunohistochemical 
tissue and cyst fluid marker for SCN, control non-SCN cysts were not included in either of these 
studies to address specificity.29, 30  
Interestingly, four cystic pancreatic neuroendocrine tumors (PNET) were also classified 
as SCN based upon a positive VEGF-A/CEA combination test (unpublished observations).  
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Although cystic PNET may be in the differential diagnosis for SCN, these lesions are extremely 
rare. PNET account for 1-2% of all pancreatic lesions with only 10-15% having cystic 
components.31, 32 Furthermore, cystic PNET are adequately identified with FNA and cytologic 
analysis. Multiple studies evaluate the accuracy of FNA for all PNET (very few or no cystic 
PNET) and report sensitivities of 83-87% and accuracy of up to 93%.33-35 Baker et al. however, 
reported 100% positive predictive value of EUS-guided FNA for cystic PNET.36 In the present 
study, of those that underwent pre-operative EUS-guided FNA (n=3), all were cytologically 
diagnosed as cystic PNET, confirming that cystic PNET are accurately diagnosed on cytologic 
examination. Taken together, diagnostic cytology must be performed prior to VEGF-A/CEA 
combination test in order to exclude possible PNETs.  
Several limitations were encountered in this study. Although 149 total pancreatic cyst 
fluid samples were included in this study, only 26 SCN were included. Of those, 22 were 
amenable to CEA measurement. Six of the 26 SCN patients had small, asymptomatic lesions of 
uncertain preoperative diagnoses that would have avoided surgery with the VEGF-A/CEA 
combination test. Despite the modest number that would definitely avoid surgery with VEGF-
A/CEA testing, all would ultimately benefit from increased confidence in diagnosis. Many 
additional patients would avoid surgery as other surgical indications such as symptoms, patient 
preference, and cyst size would play less of a role in surgical decision making if SCN diagnosis 
was certain. Existing single institution series of surgical SCN have comparable numbers due to 
the relative rarity and typical non-operative management of these lesions. Larger, multi-
institutional studies are needed to confirm findings published here. All patients in this series 
underwent surgical pancreatic resection. As many patients never receive operative care, data 
collected from surgical patients may not be generalizable to all SCN patients. Confounding 
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variables could account for the elevated VEGF-A in surgical SCN. The surgical indication might 
also contribute to VEGF-A levels (i.e. symptoms, size, growth). Our previous study examined 
cyst size as a potential confounder but confirmed no association between size and VEGF-A.12 An 
additional study limitation was the two methods used to obtain cyst fluid CEA levels, 
necessitated by the small fluid volumes available.  
Preoperative diagnosis of SCN is challenging, as supported by our findings of 63% 
misdiagnosed/not diagnosed, and contributes to unnecessary pancreatic surgical resection. 25% 
of patients undergoing operative intervention for the sole indication of lacking a clear pre-
operative diagnosis would have avoided surgery with the use of VEGF-A/CEA combination test. 
Additional patients with unclear diagnosis as part of their surgical indication might have been 
spared surgery with increased confidence in the benign diagnosis.  
 
Conclusions 
 Due to the increasing number of patients with incidentally detected pancreatic cysts 
(2.6% of those undergoing abdominal imaging)[1], surgeon awareness of available as well as 
promising diagnostic tests is important in order to effectively manage pancreatic cyst patients. In 
high risk patients with pancreatic cysts, there is an urgent need for an accurate and reliable 
diagnostic test to stratify and improve clinical care. Patients with SCN are commonly 
misdiagnosed, thus undergoing unnecessary operative intervention. Although VEGF-A alone is a 
highly accurate test for SCN, we have demonstrated that the combination of VEGF-A with CEA 
approaches the gold-standard of pathologic diagnosis (sensitivity: 95.5%, specificity: 100%). 
Patients with a positive test indicating benign SCN can be spared a high-risk surgical pancreatic 
resection.  
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Figure 1: Pancreatic Cyst Fluid VEGF-A: VEGF-A levels in pancreatic cyst fluid as 
determined by ELISA. Each VEGF-A value is shown on a log linear scale within the column 
consistent with pathologic diagnosis: SCN, pseudocyst, MCN, IPMN, or SPN. Horizontal black 
lines represent median values for each cyst type. The red dotted line is the cut-off (5,000 pg/mL) 
giving 100% sensitivity and 83.7% specificity. 
 
Figure 2: ROC Curves: ROC Curves for each biomarker alone and in combination. The AUC 
for CEA alone is 0.945, for VEGF-A alone is 0.983, and for VEGF-A/CEA Combination test is 
0.993. 
 
Figure 3: Cyst Fluid CEA: CEA levels in pancreatic cyst fluid. Each CEA value is shown on a 
log linear scale within the column consistent with pathologic diagnosis: SCN, pseudocyst, MCN, 
IPMN, or SPN. Horizontal black lines represent median values for each cyst type. The red dotted 
line is the cut-off (10 ng/mL) giving 95.5% sensitivity and 81.5% specificity. 
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Figure 4: CEA vs VEGF-A for SCN vs non-SCN: CEA vs VEGF-A for SCN vs non-SCN. 
Each point displays the cyst fluid CEA and the VEGF-A level for a single pancreatic cyst on a 
log linear scale. Blue points are SCN, and red points are all other cysts. The horizontal dashed 
line is the CEA cut-off of 10 ng/mL; all cysts plotted below this line had a positive CEA test 
result. The vertical dotted line is the VEGF-A cut-off of 5,000 pg/mL; all cysts plotted to the 
right of this line had a positive VEGF-A result. The right lower quadrant formed by the two 
threshold lines contains cysts with a positive VEGF-A/CEA combination test. These are 
exclusively SCN, demonstrating 100% specificity and infinite positive likelihood ratio of the 
combination test.  
 
Figure 5: Surgical indication of patients with SCN:  Indication for surgery in SCN patients. 
The Y axis shows the number of patients with each specific surgical indication. The frequency of 
each indication within all SCN patients is displayed at the top of each column. Many patients had 
more than one indication for surgery; each indication is represented in this graph.  
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